On Apr. 24, 2017, HitGen announced a drug discovery collaboration with the Scripps Research Institute and Calibr.

This collaboration planned to discover and develop potential new therapies in areas of unmet clinical need, with an initial focus in oncology, regenerative medicine and virology.